

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom

Element Count :

Node 13: Limited

C,C3-5


N,N1-3

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:11:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1241 TO ITERATE

100.0% PROCESSED 1241 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 22707 TO 26933

PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:11:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 23846 TO ITERATE

100.0% PROCESSED 23846 ITERATIONS
SEARCH TIME: 00.00.01

258 ANSWERS

L3 258 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 10:11:24 ON 11 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Sep 2006 VOL 145 ISS 12

FILE LAST UPDATED: 10 Sep 2006 (20060910/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 30 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:437532 CAPLUS

DOCUMENT NUMBER: 144:468184

TITLE: Pyridazine compounds as modulators of cellular pathways, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Watterson, D. Martin; Van Eldik, Linda; Haiech, Jacques; Hlibert, Marcel; Bourguignon, Jean-Jacques; Valentza, Anastasia; Hu, Wenhui; Zasadzki, Magdalena

PATENT ASSIGNEE(S): Northwestern University, USA; Universite' Louis Pasteur de Strasbourg

SOURCE: PCT Int. Appl., 236 pp. CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050389	A2	20060511	WO 2005-US39541	20051102
WO 2006050389	A3	20060706		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-624346P P 20041102
US 2005-723090P P 20051003
US 2005-723124P P 20051003

OTHER SOURCE(S): MARPAT 144:468184

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to pyridazines and related compds. of formulas I or II, which are modulators of cellular pathways. In compds. I and II, R1, R2, and R3 are independently selected from H, OH, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, etc., or R1 and R2 or R2 and R3 may form a fused heteroaryl or heterocyclyl ring; R4, R5, and R6 are independently selected from H, halo, nitro, alkyl, and alkoxy; and R7 is H, OH, alkyl, alkenyl, alkynyl, aryl, alkoxy, heteroaryl, heterocyclyl, etc., or R1 and R7 may form a fused heteroaryl or heterocyclyl ring; including isomers and pharmaceutically acceptable salts thereof. The invention also relates to the preparation of I and II, pharmaceutical compns.

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

comprising a compd. I or II and a pharmaceutically acceptable carrier, excipient, or vehicle, as well as to the use of the compns. for the treatment or prevention of inflammatory diseases, such as Alzheimer's disease. Substitution of 3-chloro-4-hydroxy-6-phenylpyridazine with 1-(pyrimidin-2-yl)piperazine gave hydroxypyridazine III, which underwent chlorination and Suzuki coupling with phenylboronic acid to give pyridazine IV. Compd. IV expressed 91% inhibition of hERG (human ether-a-go-go related gene) potassium ion channel binding.


IT 886208-63-5P, 4-(4-Pyridyl)-3-phenyl-6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate: preparation of pyridazines as modulators of cellular signaling pathways)

RN 886208-63-5 CAPLUS

CN Pyridazine, 3-phenyl-4-(4-pyridinyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:61823 CAPLUS

DOCUMENT NUMBER: 143:153709

TITLE: Synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors

INVENTOR(S): Miao, Zhenwei; Sun, Ying; Nakajima, Suanne; Tang, Datong; Wu, Frank; Xu, Guoyou; Or, Yat S.; Wang, Zhe

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 229 pp. CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153877	A1	20050714	US 2004-774047	20040206

PRIORITY APPLN. INFO.: US 2003-509069P P 20030213

OTHER SOURCE(S): MARPAT 143:153709

GI

L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The invention relates to cyclic peptides I [A = H, COR2, CO2R1, CONHR2, etc.; G = OH, alkoxy, NHCOR1, CO2R1, CONHR1, etc.; L = absent, S, SO2, O, COCH2, CF2CH2, etc.; j = 0-4; m, s = 0-2; R1, R2 = H, C1-6-alkyl, (substituted)aryl, heteroaryl, etc.; R3, R4 = H, OH, Me, CN, SH, halo, NO2, NH2, amide, MeO, CF3O, CF3; E = CH2CH2, CH2CH2; W = (un)substituted heterocyclic ring], or their pharmaceutically-acceptable salts, esters, or prodrugs, which inhibit serine protease activity, particularly the activity of HCV NS3-NS4A protease. An example is I [A = MeCO2C, G = OH, L = absent, W = 5-phenyl-1,2,3,4-tetraol-2-yl, j = 3, m, s = 1; R3, R4 = H], which was prepared via peptide coupling and ring-closing metathesis.

IT 220967-35-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)

RN 220967-35-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:510504 CAPLUS

DOCUMENT NUMBER: 143:193877

TITLE: Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticoccidial agents

AUTHOR(S): Biftu, Tesfaye; Feng, Dennis; Ponpipom, Mitree; Girotta, Narindar; Liang, Gui-Bai; Qian, Xiaoxia; Bugianesi, Robert; Simeone, Joseph; Chang, Linda; Gurnett, Anne; Liberator, Paul; Dulska, Paula; Leavitt, Penny Sue; Crumley, Tami; Misura, Andrew; Murphy, Terence; Rattray, Sandra; Samaras, Samantha; Tamas, Tamas; Mathew, John; Brown, Christine; Thompson, Don; Schatz, Dennis; Fisher, Michael; Wyvrat, Matthew

CORPORATE SOURCE: Merck Research Laboratories, Department of Medicinal Chemistry, Merck and Co., Rahway, NJ, 07065-0900, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(13), 3296-3301

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:193877

GI



AB Several analogs of 2,3-diarylpyrroles, e.g., I, were synthesized and evaluated as inhibitors of *Eimeria tenella* cGMP-dependent protein kinase and in in vivo anticoccidial assays. A 4-fluorophenyl group enhanced both in vitro and in vivo activities. The most potent analogs were the 5-(N-Me, N-Et, and N-methylazetidine methyl) piperidyl derivs. These compds. have a broad spectrum of activity. Based on the in vivo efficacy and cost of synthesis, the N-Et analog I was chosen as a anticoccidial agent for a field trial.

IT 861804-26-4P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn, parasite cGMP-dependent protein kinase binding affinity, anticoccidial activity, and structure-activity relationship of diarylpyrroles, pyridinyl(fluorophenyl)imidazole, -furan, -thiophene, -oxazole, -thiazole, and -pyridazine)

RN 861804-26-4 CAPLUS

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:331950 CAPLUS

DOCUMENT NUMBER: 143:43843

TITLE: Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase

AUTHOR(S): Tamayo, Nuria; Liao, Lillian; Goldberg, Martin; Powers, David; Tudor, Yan-Yan; Yu, Violeta; Wong, Lu Min; Henkle, Bradley; Middleton, Scott; Syed, Rashid; Harvey, Timothy; Jang, Graham; Hungate, Randall; Dominguez, Celia

CORPORATE SOURCE: Chemistry Research and Discovery, Amgen, Inc., Thousand Oaks, CA, 91320, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(9), 2409-2413

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:43843

AB Novel potent trisubstituted pyridazine inhibitors of p38 MAP (mitogen activated protein) kinase are described that have activity in both cell-based assays of cytokine release and animal models of rheumatoid arthritis. They demonstrated potent inhibition of LPS-induced TNF- α production in mice and exhibited good efficacy in the rat collagen induced arthritis model.


IT 853730-50-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)

RN 853730-50-4 CAPLUS

CN Pyridazine, 3-(2-naphthalenyl)-6-[(3R)-3-(phenylmethyl)-1-piperazinyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 271247-18-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)

RN 271247-18-8 CAPLUS


CN 2-Pyrididinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte

L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Pyridazine, 3-(4-fluorophenyl)-6-(1-methyl-4-piperidinyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT 861804-58-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn, parasite cGMP-dependent protein kinase binding affinity, anticoccidial activity, and structure-activity relationship of diarylpyrroles, pyridinyl(fluorophenyl)imidazole, -furan, -thiophene, -oxazole, -thiazole, and -pyridazine)

RN 861804-58-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[6-(4-fluorophenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 271247-22-4P 853730-36-6P 853730-37-7P

853730-38-8P 853730-39-9P 853730-43-5P

853730-44-6P 853730-45-7P 853730-46-8P

853730-47-9P 853730-48-0P 853730-49-1P


853730-51-5P 853730-52-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)

RN 271247-22-4 CAPLUS

CN 2-Pyrididinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 853730-36-6 CAPLUS

09/11/2006

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzamide, N-methyl-N-[4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 853730-37-7 CAPLUS
 CN Benzamide, 4-fluoro-N-methyl-N-[4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 853730-38-8 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(4-fluorophenyl)ethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A

RN 853730-43-5 CAPLUS
 CN 1,2-Propanediamine, 3-phenyl-N1-[5-(4-pyrimidinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-44-6 CAPLUS
 CN 1,2-Propanediamine, 2-methyl-3-phenyl-N1-[5-(4-pyrimidinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 853730-45-7 CAPLUS
 CN 1,2-Propanediamine, N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-3-phenyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853730-39-9 CAPLUS
 CN Piperidine, 1-[(2R)-2-hydroxy-1-oxopropyl]-4-[5-[2-[[1S]-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853730-46-8 CAPLUS
 CN 1,2-Propanediamine, 3-(4-fluorophenyl)-N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853730-47-9 CAPLUS
 CN 1,2-Propanediamine, N2-(1-methylethyl)-N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-3-phenyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853730-48-0 CAPLUS
 CN 3-Pyridazinamine, 6-(2-naphthalenyl)-N-[(2R)-3-phenyl-2-(1-pyrrolidinyl)propyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853730-49-1 CAPLUS
 CN Acetamide, 2-hydroxy-N-((1R)-1-[[[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]amino]methyl]-2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-51-5 CAPLUS
 CN Pyridazine, 6-[[[3R]-3-(2-methylpropyl)-1-piperazinyl]-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-52-6 CAPLUS
 CN Piperazine, 1-(hydroxyacetyl)-4-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-2-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[[[1S]-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-42-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-fluoro-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 271247-34-8P 271247-35-9P 271247-36-0P
 271247-42-8P 271247-43-9P 629623-78-5P
 629623-79-6P 853730-34-4P 853730-35-5P
 853730-41-3P 853730-42-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)

RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 271247-43-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[[[1S]-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 629623-78-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-naphthalenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 629623-79-6 CAPLUS
CN Pyridazine, 6-chloro-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 853730-34-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylamino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 853730-35-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1-(4-fluorophenyl)ethyl)amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ester (9CI) (CA INDEX NAME)

RN 853730-41-3 CAPLUS
CN 3(2H)-Pyridazinone, 5-(4-pyrimidinyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 853730-42-4 CAPLUS
CN Pyridazine, 6-chloro-4-(4-pyrimidinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:927172 CAPLUS
DOCUMENT NUMBER: 141:395567
TITLE: Preparation of substituted pyridazines and analogs for treatment of TNF- α , IL-1 β , IL-6, and/or IL-8 mediated disorders
INVENTOR(S): Dominguez, Celis; Goldberg, Martin H.; Tamayo, Nuria A.
PATENT ASSIGNER(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094379	A2	20041104	WO 2004-US11953	20040415
WO 2004094379	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SO, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004254178	A1	20041216	US 2004-826982	20040415
EP 1628665	A2	20060301	EP 2004-750293	20040415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.: US 2003-463697P 20030416 WO 2004-US11953 W 20040415				
OTHER SOURCE(S): MARPAT 141:395567 GI				

own work

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



II

- AB Title compds. I [wherein X1, X2 = independently (un)substituted CH, N, with the proviso that at least one of X1 and X2 = N; R1 = (halo)alkyl, CN, NO₂, acyl, carboxy, carbamoyl, alkoxy, sulfamoyl, ureido, etc.; R2 = alkyl, Ph, PhCH₂, heterocyclyl, etc.; R3, R4 = independently (un)substituted Ph, naphthyl, heterocyclyl or pharmaceutically acceptable salts thereof] were prepared as TNF- α , IL-1 β , IL-6, and/or IL-8 inhibitors. For example, a multi-step synthesis concluding with the reaction of 4-[5-(2-methanesulfonylpyrimidin-4-yl)-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester and (S)-(-)-1-phenylethylamine gave II. The latter inhibited lipopolysaccharide-activated THP1 cell TNF- α production with IC₅₀ <20 μ M. Thus, I and their pharmaceutical compns. are useful for the treatment of inflammation, rheumatoid arthritis, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic b cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses, or herpes zoster infection (no data).
- IT 786705-13-3P, 4-[4-Methyl-5-(2-methylsulfonylpyrimidin-4-yl)-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-15-5P, 4-[5-(2-Methylsulfonylpyrimidin-4-yl)-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-17-7P, 4-[4-Methyl-5-[2-(1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-19-9P, 4-[5-Methyl-6-(piperidin-4-yl)-3-(3-trifluoromethylphenyl)pyridazin-4-

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


yl]pyrimidin-2-yl] (1-phenylethyl)amine 786705-21-3P, 2-Hydroxy-1-[4-[4-methyl-5-[2-(1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidin-1-yl]propan-1-one 786705-23-5P, (S)-4-[4-Methyl-5-[2-(1-phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-25-7P, 4-[5-Methyl-6-(piperidin-4-yl)-3-(3-trifluoromethylphenyl)pyridazin-4-yl]pyrimidin-2-yl] ((S)-1-phenylethyl)amine 786705-27-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(TNF and/or IL inhibitors; prepn. of substituted pyridazines and analogs as TNF and IL inhibitors for treatment inflammation, pain, and other disorders)

RN 786705-13-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 786705-15-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 786705-17-7 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-[[1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 786705-19-9 CAPLUS


CN 2-Pyrimidinamine, 4-[5-methyl-6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 786705-21-3 CAPLUS


CN Piperidine, 1-[2-hydroxy-1-oxopropyl]-4-[4-methyl-5-[2-[[1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 786705-23-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-[[1S]-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:951017 CAPLUS

DOCUMENT NUMBER: 140:16737

TITLE:

Preparation of substituted heterocyclic compounds as inhibitors of TNF- α
 Dominguez, Celina; Zhang, Dawei; Cao, Guo-Qiang;
 Goldberg, Martin H.; Hong, Fang-Tsao; Sham, Kelvin K.
 C.; Tadese, Seifu; Tamayo, Nuria A.; Weiler, Kurt E.;
 Liao, Hongyu

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099808	A1	20031204	WO 2003-US15473	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, CN, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2485166	AA	20031204	CA 2003-2485166	20030513
US 2005038010	A1	20050217	US 2003-438553	20030513
US 7026326	B2	20060411		
AU 2003234628	A1	20031212	AU 2003-234628	20030515
EP 1506186	A1	20050216	EP 2003-728971	20030515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005530810	T2	20051013	JP 2004-507465	20030515
PRIORITY APPL. INFO.:			US 2002-382699P	P 20020521
			WO 2003-US15473	W 20030515

OTHER SOURCE(S):


GI

MARPAT 140:16737




II

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 629623-79-6 CAPLUS

CN Pyridazine, 6-chloro-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

AB Title compds. I [R1 = (un)saturated 5-7 membered, optionally benzo-fused, (hetero)cyclo; R2 = alkyl, etc.; R3-4 = (un)substituted Rcr = aryl, (un)saturated 5-7 membered, optionally benzo-fused, heterocyclo; X, V, W = N,;

NRS, CR6, C:O, etc.; R5 = H, alkyl; R6 = alkyl] are prepared For instance, (R)-2-aminomethylpyrrolidine-1-carboxylic acid tert-Bu ester (preparation given) is deprotected (dioxane, HCl) and reacted with 2-chloro-5-(4-chlorophenyl)-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (K2CO3) to give II as a yellow solid. Example compds. exhibit activities in the THP1 cell assay (LPS induced TNF release) with IC50 of 20 μ M or less. I are useful in the treatment of inflammation, rheumatoid arthritis, Pagets disease, etc.

IT 629623-49-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(substituted pyridine/pyrimidine analogs as inhibitors of TNF- α)

RN 629623-49-0 CAPLUS

CN 2-Pyrrolidinemethanamine, N-(1-methylethyl)-1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 629623-78-5P 629623-79-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(substituted pyridine/pyrimidine analogs as inhibitors of TNF- α)

RN 629623-78-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-naphthalenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:849586 CAPLUS

DOCUMENT NUMBER: 137:370099

TITLE:

Preparation of 3-aminopyrazolo[3,4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of gsk-3 β protein and protein complexes

Ter Haar, Ernst; Swenson, Lovorka; Green, Jeremy;

Arnost, Michael J.

Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 778 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088078	A2	20021107	WO 2002-US13511	20020429
WO 2002088078	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, EE, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GM, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444882	AA	20021107	CA 2002-2444882	20020429
AU 2002259071	A1	20021111	AU 2002-259071	20020429
US 2003125332	A1	20030703	US 2002-135255	20020429
EP 1435957	A2	20040714	EP 2002-729056	20020429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005504731	T2	20050217	JP 2002-585380	20020429
PRIORITY APPL. INFO.:			US 2001-287366P	P 20010430
			US 2001-297094P	P 20010608
			US 2002-361899P	P 20020227
			WO 2002-US13511	W 20020429

OTHER SOURCE(S):

GI

MARPAT 137:370099



AB Title compds. [I: R1 = H, RCO, RO2C, (substituted) alipharyl, carbocyclyl, heterocyclyl, heteroaryl, etc.; R2, R3 = H, (substituted) alipharyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl, NR2,

L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NROR, SR, OR, CF3, halo, NO2, cyano, etc.; R = H, (substituted)
 aliphatic, carbocyclic, heterocyclic, aryl, aralkyl, heteroaryl,
 heteroaralkyl, were prepd. Thus, 3-chloro-4-cyano-5,6-diphenylpyridazine
 was refluxed with NH4 in EtOH to give 3-amino-4,5-diphenyl-1H-
 pyrazolo[3,4-c]pyridazine. The latter inhibited gsk-3 with Ki 0.1
 μM.


IT 474380-93-3P 474380-94-4P 474380-95-5P
 474381-17-4P 474381-19-6P 474381-25-4P
 474381-27-6P 474381-33-4P 474381-35-6P
 474381-66-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(Preparation of pyrazolopyridazines as inhibitors of gsk-3 and crystal
 structures of gsk-3β protein and protein complexes)


RN 474380-93-3 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-phenyl-4-(2-pyridinyl)- (9CI) (CA
 INDEX NAME)



RN 474380-94-4 CAPLUS


CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-phenyl-4-(3-pyridinyl)- (9CI) (CA
 INDEX NAME)



RN 474380-95-5 CAPLUS


CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-phenyl-4-(4-pyridinyl)- (9CI) (CA
 INDEX NAME)

L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474381-27-6 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(3-methoxyphenyl)-4-(3-pyridinyl)-
 (9CI) (CA INDEX NAME)




RN 474381-33-4 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(4-methylphenyl)-4-(3-pyridinyl)-
 (9CI) (CA INDEX NAME)




RN 474381-35-6 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(4-methylphenyl)-4-(4-pyridinyl)-
 (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 474381-17-4 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-chlorophenyl)-4-(4-pyridinyl)-
 (9CI) (CA INDEX NAME)



RN 474381-19-6 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-chlorophenyl)-4-(3-pyridinyl)-
 (9CI) (CA INDEX NAME)




RN 474381-25-4 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(3-methoxyphenyl)-4-(4-pyridinyl)-
 (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 474381-66-3 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 4-[2-(methylthio)-4-pyrimidinyl]-5-
 phenyl- (9CI) (CA INDEX NAME)




09/11/2006

L4 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:508086 CAPLUS
 DOCUMENT NUMBER: 137:337848
 TITLE: Pyridazine derivatives. XXIV. Efficient N-methylation of diversely substituted 3(2H)-pyridazinones using N,N-dimethylformamide dimethylacetal
 AUTHOR(S): Sotelo, Eddy; Ravina, Enrique
 CORPORATE SOURCE: Departamento de Química Organica, Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, 15782, Spain
 SOURCE: Synthetic Communications (2002), 32(11), 1675-1680
 CODEN: SYNCAV; ISSN: 0039-7911
 PUBLISHER: Marcel Dekker, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:337848
 GI



AB A series of diversely substituted 3(2H)-pyridazinones, e.g., I, were efficiently N-methylated at position 2 by treatment with N,N-dimethylformamide dimethylacetal in DMF.


IT 220967-35-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of methylated pyridazinones via N-methylation of pyridazinones with N,N-dimethylformamide dimethylacetal)
 RN 220967-35-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 443958-86-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-morpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 271247-18-8P 271247-34-8P 271247-35-9P
 271247-36-0P 344465-97-0P 344465-98-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridazine based inhibitors of p38 MAPK)
 RN 271247-18-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




Habte

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:116978 CAPLUS
 DOCUMENT NUMBER: 137:125130
 TITLE: Pyridazine based inhibitors of p38 MAPK
 AUTHOR(S): McIntyre, Charles J.; Ponticello, Gerald S.; Liverton, Nigel J.; O'Keefe, Stephen J.; O'Neill, Edward A.; Pang, Margaret; Schwartz, Cheryl D.; Claremon, David A.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 689-692
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:125130
 AB Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group α and a heteroaryl group β relative to the nitrogen atom in the 2-position of the central pyridazine. Addnl., substitution in the 6-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC50 1-20 nM) in vitro activity.
 IT 271247-37-1P 443958-86-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of pyridazine based inhibitors of p38 MAPK)
 RN 271247-37-1 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/11/2006

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-97-0 CAPLUS
 CN 3-(2H)-Pyridazinone, 5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-98-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-chloro-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-84-2 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-91-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 344464-67-1P 344464-83-1P 344464-84-2P
 344464-91-1P 344464-93-3P 344464-96-6P
 RL: SYN (Synthetic preparation); PREP (Preparation)
 (preparation of pyridazine based inhibitors of p38 MAPK)
 RN 344464-67-1 CAPLUS
 CN 3-Pyridazinamine, N,N-dimethyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-83-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-93-3 CAPLUS
 CN 1,2-Ethanediimine, N,N,N'-trimethyl-N'-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-96-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:51440 CAPLUS
 DOCUMENT NUMBER: 136:102392
 TITLE: Preparation of phenylpyridazine derivatives as inhibitors of interleukin 1 β production
 INVENTOR(S): Ohkuchi, Masao; Kyotani, Yoshinori; Shigyo, Hiromichi; Koshi, Tomoyuki; Ohgiya, Tadaaki; Matsuda, Takayuki; Kumai, Natsuyo; Yasuoka, Kyoko
 PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 70 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004427	A1	20020117	WO 2001-JP5904	20010706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BU, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6664256	B1	20031216	US 2000-612953	20000710
CA 2413042	A1	20020117	CA 2001-2413042	20010706
AU 2001069474	A5	20020121	AU 2001-69474	20010706
EP 1300399	A1	20030409	EP 2001-947902	20010706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 523242	A	20041029	NZ 2001-523242	20010706
RU 2269519	C2	20060210	RU 2003-103780	20010706
TW 593285	B	20040621	TW 2001-90116864	20010710
NO 2003000097	A	20030109	NO 2003-97	20030109
PRIORITY APPLN. INFO.: US 2000-612953 A 20000710 WO 2001-JP5904 W 20010706				
OTHER SOURCE(S): MARPAT 136:102392 GI				

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Comps. of the general formula (I) or salts thereof [wherein R1 is optionally substituted Ph or pyridyl; R2 is lower alkoxy, lower alkylthio, lower alkylsulfinyl, or lower alkylsulfonyl; R3 is hydrogen or lower alkoxy; or R2 and R3 together form a alkylenedioxy group; and R4 is hydrogen, halo, cyano, CO₂H, each optionally substituted lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylsulfonyloxy, aromatic hydrocarbyl, aromatic heterocyclyl, phenoxy, phenylthio, phenylsulfinyl, phenylsulfonyl, pyridyloxy, morpholino, morpholinocarbonyl, piperidinocarbonyl, 1-piperazinylcarbonyl, or NH₂; n = 0, 1] are prepared. The comps. I exhibit an excellent interleukin 1 β production inhibiting activity and are useful as preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β such as immunol. diseases, inflammatory diseases, ischemic disease, osteoporosis, septicemia, rheumatism, arthritis, and inflammatory colitis. Thus, 2,3,4,5,6-pentafluorophenol and K₂CO₃ were added to a solution of 6-chloro-3-(4-methoxyphenyl)-4-phenylpyridazine in DMF and stirred at 80° for 7 h to give 30.5% 3-(4-methoxyphenyl)-6-(2,3,4,5,6-pentafluorophenoxy)-4-phenylpyridazine (II). II showed IC₅₀ of 0.01 μ M for inhibiting the production of interleukin-1 β in HL-60 cells.

IT 388606-34-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylpyridazine derivs. as inhibitors of interleukin 1 β production and preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β)
 RN 388606-34-6 CAPLUS
 CN Pyridazine, 6-(2,4-difluorophenoxy)-3-(4-methoxyphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT 225666-37-5


Habte

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of phenylpyridazine derivs. as inhibitors of interleukin 1 β prodn. and preventive and therapeutic drugs for diseases caused by increased prodn. of interleukin 1 β)
 RN 225666-37-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT 388606-33-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phenylpyridazine derivs. as inhibitors of interleukin 1 β production and preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β)
 RN 388606-33-5 CAPLUS
 CN Pyridazine, 6-chloro-3-(4-methoxyphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/11/2006

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:435072 CAPLUS
 DOCUMENT NUMBER: 135:46188
 TITLE: Substituted pyridazines having cytokine inhibitory activity
 INVENTOR(S): McIntyre, Charles J.; Liverston, Nigel J.; Claremon, David A.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042241	A1	20010614	WO 2000-0533097	20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, SV, TC, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TG				
US 6602872	B1	20030805	US 2000-717277	20001121
CA 2392584	AA	20010614	CA 2000-2392584	20001207
EP 1240160	A1	20020918	EP 2000-986274	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517477	T2	20030527	JP 2001-543540	20001207
PRIORITY APPLN. INFO.:			US 1999-170319P	P 19991213
			WO 2000-0533097	W 20001207
OTHER SOURCE(S):	MARPAT	135:46188		
GI				




AB Pyridazines I [A is halogen, Ph, PhS(O)m (m = 0-2), or R5R6N; R1 is H, alkylamino, or (un)substituted arylamino; R2, R3, R4 are independently halogen, hydroxy, F3C, amino, nitro, (C1-C6)alkyl, (C1-C6)alkoxy,

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (C3-C8)cycloalkyl, Ph, R5 and R6 are independently hydrogen, alkoxy-, (un)substituted amino-, and (un)substituted phenyl-substituted (or unsubstituted) (C1-C6)alkyl or R5R6 = (C4-C10)(un)substituted (mono- or bicyclic)heterocycle; Q is CH or N) are prepd. as inhibitors or antagonists of the formation and activity of cytokines such as interleukin-1 β (IL-1 β), IL-6, and IL-8 for the treatment of cytokine mediated diseases and conditions such as inflammation, arthritis, sepsis and septic shock, osteoporosis, bone resorption diseases, and Crohn's disease. E.g., the dihydrochloride of I [A = Me2NCH2CH2NH; R1 = (S)-PhCH(Me)NH; R2 = 3-F3C; R3 = R4 = H] (II) was prepd. by amidation of 3-trifluoromethylbenzoyl chloride with N-methoxymethylamine, displacement of the amide with 2-(methylthio)-4-pyridinylmethylthium, alkylation of the ketone with Me bromoacetate, hydrolysis of the ester with hydrogen chloride in dioxane, addn. and cyclization of the acid and ketone moieties with hydrazine, oxidn. of the methylthio group to the pyrimidinyl Me sulfone with sodium tungstate and hydrogen peroxide, addn. of (S)- α -methylbenzylamine to the pyrimidinyl sulfone with substitution to give the pyrimidinamine, oxidn. of the cyclic hydrazone to the hydroxypyridazine with DDQ, and chlorination of the hydroxypyridazine with phosphorus oxychloride to give I [A = Cl; R1 = (S)-PhCH(Me)NH; R2 = 3-F3C; R3 = R4 = H], a key intermediate in the prepn. of the claimed pyridazines. E.g., treatment of I [A = Cl; R1 = (S)-PhCH(Me)NH; R2 = 3-F3C; R3 = R4 = H] with 2-(dimethylamino)ethylamine and heating at 100° gave II as the free base which was converted to the hydrochloride by treatment with 1N HCl. No biol. data is provided.
 IT 344464-70-6P 344464-73-9P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyridazine derivs. as inhibitors of cytokine formation and activity for the treatment of cytokine-mediated diseases such as arthritis)
 RN 344464-70-6 CAPLUS
 CN 344464-70-6 [1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A

RN 344464-73-9 CAPLUS
 CN 2-Pyrimidinamine, N-[[[1S]-1-phenylethyl]-4-[6-(phenylthio)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 344464-66-0P 344464-67-1P 344464-68-2P
 344464-69-3P 344464-71-7P 344464-72-8P


Habte

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

344464-74-0P 344464-75-1P 344464-76-2P
 344464-77-3P 344464-78-4P 344464-79-5P
 344464-80-6P 344464-81-7P 344464-82-0P
 344464-83-1P 344464-84-2P 344464-85-3P
 344464-86-4P 344464-87-5P 344464-88-6P
 344464-89-7P 344464-90-0P 344464-91-1P
 344464-92-2P 344464-93-3P 344464-94-4P
 344464-95-5P 344464-96-6P 344464-97-7P
 344464-98-8P 344464-99-9P 344465-00-5P
 344465-01-6P 344465-02-7P 344465-03-8P
 344465-04-9P 344465-05-0P 344465-06-1P
 344465-07-2P 344465-08-3P 344465-09-4P
 344465-10-7P 344465-11-8P 344465-12-9P
 344465-13-0P 344465-14-1P 344465-15-2P
 344465-16-3P 344465-17-4P 344465-18-5P
 344465-19-6P 344465-20-9P 344465-21-0P
 344465-22-1P 344465-23-2P 344465-24-3P
 344465-25-4P 344465-26-5P 344465-27-6P
 344465-28-7P 344465-29-8P 344465-31-2P
 344465-33-4P 344465-34-5P 344465-35-6P
 344465-36-7P 344465-37-8P 344465-38-9P
 344465-40-3P 344465-42-5P 344465-44-7P
 344465-46-9P 344465-48-1P 344465-50-5P
 344465-52-7P 344465-53-8P 344465-54-9P
 344465-55-0P 344465-56-1P 344465-57-2P
 344465-58-3P 344465-59-4P 344465-60-7P
 344465-61-8P 344465-62-9P 344465-63-0P
 344465-64-1P 344465-65-2P 344465-66-3P
 344465-67-4P 344465-68-5P 344465-69-6P
 344465-70-9P 344465-71-0P 344465-72-1P
 344465-73-2P 344465-74-3P 344465-75-4P
 344465-76-5P 344465-77-6P 344465-78-7P
 344465-79-8P 344465-80-1P 344465-81-2P
 344465-82-3P 344465-83-4P 344465-84-5P
 344465-85-6P 344465-86-7P 344465-87-8P
 344465-88-9P 344465-89-0P 344465-90-3P
 344465-91-4P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridazine derivs. as inhibitors of cytokine formation and activity for the treatment of cytokine-mediated diseases such as arthritis)
 RN 344464-66-0 CAPLUS
 CN 1,2-Ethanediimine, N,N-dimethyl-N'-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

09/11/2006

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●2 HCl

RN 344464-67-1 CAPLUS

CN 3-Pyridazinamine, N,N-dimethyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-68-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-morpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●3 HCl

RN 344464-72-8 CAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-phenyl-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-74-0 CAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(phenylsulfinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●2 HCl

RN 344464-69-3 CAPLUS

CN 1,2-Ethanediamine, N-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]]-3-pyridazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 344464-71-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(4-amino-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-75-1 CAPLUS

CN 3-Pyridazinamine, N-(3-methoxypropyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-76-2 CAPLUS

CN 3-Pyridazinamine, N-(3-ethoxypropyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-77-3 CAPLUS
 CN 3-Pyridazinamine, N-[3-(1H-imidazol-1-yl)propyl]-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-78-4 CAPLUS
 CN 3-Pyridazinamine, 5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-[1-(phenylethyl)-4-piperidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-81-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-82-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-79-5 CAPLUS
 CN Carbamic acid, 2-[[[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]amino]ethyl]-, 1,1-dimethylester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-80-8 CAPLUS
 CN 3-Pyridazinamine, N-[(3,4-dimethoxyphenyl)methyl]-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-83-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-84-2 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-85-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,4-dihydro-2(1H)-isoquinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-86-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,5-dimethyl-1-piperidiny)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-89-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-90-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(4-fluorophenyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-87-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[1,4'-bipiperidin]-1'-yl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-88-6 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-(1-methyl-3-pyrrolidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-91-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperidiny)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-92-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-1-piperidiny)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-93-3 CAPLUS
 CN 1,2-Ethanediamine, N,N,N'-trimethyl-N'-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-94-4 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperazinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-97-7 CAPLUS
 CN 3-Pyridazinamine, N,N-bis(2-methoxyethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-98-8 CAPLUS
 CN 3-Pyridazinamine, N-(cyclopropylmethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-95-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(octahydro-1(2H)-quinolinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-96-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344464-99-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-00-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2,6-dimethyl-4-morpholinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-01-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-thiomorpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-02-7 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-05-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-(3,4-dimethylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-06-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-03-8 CAPLUS
 CN 3-Pyridazinamine, N-ethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-04-9 CAPLUS
 CN 3-Pyridazinamine, N,N-dibutyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-07-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-(4-methoxyphenyl)-3-methyl-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-08-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(hexahydro-1H-azepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-09-4 CAPLUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-2-propynyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-10-7 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-13-0 CAPLUS
 CN 3-Pyridazinamine, N-(2-phenylethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-14-1 CAPLUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-[2-(2-pyridinyl)ethyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-11-8 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-(1-methyl-4-piperidinyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-12-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-15-2 CAPLUS
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-16-3 CAPLUS
 CN 3-Piperidinecarboxamide, 1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-[2-(2-pyridinyl)ethyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-17-4 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-18-5 CAPLUS
 CN 1H-Indole-3-ethanamine, N-methyl-N-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-21-0 CAPLUS
 CN 4-Piperidinol, 4-(4-bromophenyl)-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-22-1 CAPLUS
 CN 3-Pyridazinamine, N-(2-methoxyethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-propyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-19-6 CAPLUS
 CN 4-Piperidinol, 4-phenyl-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-20-9 CAPLUS
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-23-2 CAPLUS
 CN 3-Pyridazinamine, N-ethyl-N-(2-methoxyethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-24-3 CAPLUS
 CN 3-Pyridazinamine, N-(2-methoxyethyl)-N-methyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-25-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-26-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-27-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(2-phenyl-1H-imidazol-1-yl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-28-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-29-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-31-2 CAPLUS
 CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-33-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(2,5-dimethylphenyl)-1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-34-5 CAPLUS
 CN Carbamic acid, [2-[[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]amino]ethyl]-, 1,1-dimethylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

RN 344465-35-6 CAPLUS
 CN 3-Pyridazinamine, N-[(3,4-dimethoxyphenyl)methyl]-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 344465-36-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CH 1

CRN 344464-85-3
 CMF C32 H27 F3 N6

Absolute stereochemistry.



CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 344465-40-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,5-dimethyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344464-86-4
 CMF C30 H31 F3 N6

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●3 HCl

RN 344465-37-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●3 HCl

RN 344465-38-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,4-dihydro-2(1H)-isoquinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 344465-42-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[1,4'-bipiperidin]-1'-yl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344464-87-5
 CMF C33 H36 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-44-7 CAPLUS
CN 3-Pyridazinamine, N-methyl-N-(1-methyl-3-pyrrolidinyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 344464-88-6
CMF C29 H30 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-46-9 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 344464-89-7
CMF C29 H30 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 344465-48-1 CAPLUS
CN 2-Pyrimidinamine, 4-[6-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 344464-90-0
CMF C33 H29 F4 N7

Absolute stereochemistry.



L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 344465-50-5 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 344464-91-1
CMF C29 H29 F3 N6

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2

Habte

09/11/2006

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-52-7 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(3-methyl-1-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-92-2
CMF C29 H29 F3 N6

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344465-53-8 CAPLUS

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344465-55-0 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(octahydro-1(2H)-quinoliny)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-95-5
CMF C32 H33 F3 N6


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2-Ethanediamine, N,N,N'-trimethyl-N'-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-93-3
CMF C28 H30 F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 344465-54-9 CAPLUS
CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-94-4
CMF C33 H30 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 344465-56-1 CAPLUS
CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-57-2 CAPLUS
 CN 3-Pyridazinamine, N,N-bis(2-methoxyethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl], bis(trifluoroacetate) (9CI)
 (CA INDEX NAME)

CH 1

CRN 344464-97-7
 CMF C29 H31 F3 N6 O2

Absolute stereochemistry.



CH 2


CRN 76-05-1
 CMF C2 H F3 O2

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CH 1

CRN 344464-99-9
 CMF C40 H35 Cl F3 N7

Absolute stereochemistry.



CH 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 344465-60-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2,6-dimethyl-4-morpholinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-00-5
 CMF C29 H29 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-58-3 CAPLUS

CN 3-Pyridazinamine, N-[(cyclopropylmethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-propyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344464-98-8
 CMF C30 H31 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 344465-59-4 CAPLUS

CN 2-Pyrimidinamine, 4-[6-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 344465-61-8 CAPLUS


CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-thiomorpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-01-6
 CMF C27 H25 F3 N6 S

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-62-9 CAPLUS
CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 344465-02-7
CMF C34 H31 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-63-0 CAPLUS
CN 3-Pyridazinamine, N-ethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 344465-03-6
CMF C32 H29 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-64-1 CAPLUS
CN 3-Pyridazinamine, N,N-dibutyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 344465-04-9
CMF C31 H35 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-65-2 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(3,4-dimethylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 344465-05-0
CMF C35 H34 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-66-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-06-1

CMF C34 H32 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-67-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methoxyphenyl)-3-methyl-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-07-2

CMF C35 H34 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-68-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(hexahydro-1H-azepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-08-3

CMF C29 H29 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-69-6 CAPLUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-2-propynyl]-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-09-4

CMF C27 H23 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-70-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-10-7

CMF C31 H31 F3 N6 O2

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-71-0 CAPLUS

CN 3-Pyridazinamine, N-methyl-N-(1-methyl-4-piperidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-11-8

CMF C30 H32 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-72-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-12-9

CMF C29 H29 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-73-2 CAPLUS

CN 3-Pyridazinamine, N-(2-phenylethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-13-0

CMF C38 H33 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-74-3 CAPLUS

CN 3-Pyridazinamine, N-methyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-(2-(2-pyridinyl)ethyl)-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-14-1

CMF C31 H28 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-75-4 CAPLUS

CN 3-Piperidinecarboxamide, N,N-diethyl-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-15-2

CMF C33 H36 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-76-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-16-3

CMF C29 H28 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-77-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-17-4

CMF C29 H28 F3 N7 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-78-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-methyl-N-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-18-5
CMF C34 H30 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-79-8 CAPLUS
CN 4-Piperidinol, 4-phenyl-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-19-6
CMF C34 H31 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-80-1 CAPLUS
CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-20-9
CMF C34 H30 Cl F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 344465-81-2 CAPLUS
CN 4-Piperidinol, 4-(4-bromophenyl)-1-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
CRN 344465-21-0
CMF C34 H30 Br F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-82-3 CAPLUS

CN 3-Pyridazinamine, N-(2-methoxyethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-propyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-22-1

CMF C29 H31 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-83-4 CAPLUS

CN 3-Pyridazinamine, N-ethyl-N-(2-methoxyethyl)-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-23-2

CMF C28 H29 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-84-5 CAPLUS

CN 3-Pyridazinamine, N-(2-methoxyethyl)-N-methyl-5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-24-3

CMF C27 H27 F3 N6 O

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-85-6 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(2-methyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 344465-25-4

CMF C27 H22 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-86-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-26-5

CMF C33 H26 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-87-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(2-phenyl-1H-imidazol-1-yl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-27-6

CMF C32 H24 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-88-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-28-7

CMF C35 H32 F3 N7 O2

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344465-89-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethylamino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344465-29-8

CMF C30 H30 F3 N7 O2

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-90-3 CAPLUS
CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-31-2
CMF C29 H32 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


IT 344465-97-0P 344465-98-1P 344465-99-2P
344466-00-8P 344466-01-9P 344466-02-0P
344466-03-1P 344466-04-2P 344466-05-3P
344466-06-4P 344466-07-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
and (preparation of pyridazine derivs. as inhibitors of cytokine formation and activity for the treatment of cytokine-mediated diseases such as arthritis)

RN 344465-97-0 CAPLUS
CN 3(2R)-Pyridazinone, 5-[2-[[[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 344465-91-4 CAPLUS
CN 2-Pyrimidinamine, 4-[6-[4-(2,5-dimethylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-33-4
CMF C35 H34 F3 N7


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-98-1 CAPLUS
CN 2-Pyrimidinamine, 4-[6-chloro-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-99-2 CAPLUS
CN 3(2R)-Pyridazinone, 5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-00-8 CAPLUS
CN Pyridazine, 6-chloro-4-[2-(methylthio)-4-pyrimidinyl]-3-[3-

09/11/2006


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 344466-01-9 CAPLUS
CN 3-Pyridazinamine, N,N-dimethyl-5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-02-0 CAPLUS
CN 3-Pyridazinamine, N,N-dimethyl-5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-03-1 CAPLUS
CN Methanesulfonic acid, trifluoro-, 5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344466-06-4 CAPLUS
CN Pyridazine, 4-[2-(methylthio)-4-pyrimidinyl]-6-phenyl-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-07-5 CAPLUS
CN Pyridazine, 4-[2-(methylsulfonyl)-4-pyrimidinyl]-6-phenyl-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Habte

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344466-04-2 CAPLUS
CN Morpholine, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 344466-05-3 CAPLUS
CN Morpholine, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:368342 CAPLUS
DOCUMENT NUMBER: 133:4673
TITLE: Preparation of azines as cytokine inhibitors
INVENTOR(S): Claremon, David A.; Ponticello, Gerald S.
PATENT ASSIGNER(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PFXK02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031065	A1	20000602	WO 1999-US27184	19991116
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6350744	B1	20020226	US 1999-433247	19991104
CA 2350969	AA	20000602	CA 1999-2350969	19991116
EP 1131314	A1	20010912	EP 1999-960406	19991116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002530399	T2	20020917	JP 2000-583893	19991116
AU 755862	B2	20030123	AU 2000-17297	19991116
PRIORITY APPL. INFO.:			US 1998-109306P	P 19981120
			WO 1999-US27184	W 19991116
OTHER SOURCE(S):			MARPAT 133:4673	
GI				




AB Title compds. [I; A = H, (N-alkylated) pyrrolidinyl, morpholinyl, piperidinyl; Q, U, V, W = CH, N; R1 = H, aralkylamino; R2-R4 = H, halo, OH, CF3, amino, NO2, (substituted) alkyl, alkoxy, cycloalkyl, aryl], were prepared as cytokine inhibitors (no data). Thus, title compound (II) was prepared in several steps via 4-[2-(methylthio)pyrimidin-4-yl]-3-

09/11/2006

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IT 271247-18-8P 271247-19-9P 271247-20-2P
 271247-21-3P 271247-22-4P 271247-23-5P
 271247-37-1P 271247-38-2P 271247-41-7P
 271247-44-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azines as cytokine inhibitors)
 RN 271247-18-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-19-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 271247-22-4 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271247-23-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 271247-37-1 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-

Habte


L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 271247-20-2 CAPLUS
 CN Pyridazine, 6-(1-methyl-4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 271247-21-3 CAPLUS
 CN Pyridazine, 6-(4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Pyridazine, 6-(1-methyl-4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• 2 HCl

RN 271247-38-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 271247-41-7 CAPLUS
 CN Pyridazine, 6-(4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)

09/11/2006


L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 3 HCl

RN 271247-44-0 CAPLUS
 CN 2-Pyridinamine, 4-[6-(1-methyl-4-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

IT 271247-34-8P 271247-35-9P 271247-36-0P
 271247-40-6P 271247-42-8P 271247-43-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of azines as cytokine inhibitors)
 RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 271247-40-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-42-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(2-fluoro-4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

*intermediate*


RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

*intermediate*

RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 271247-43-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1999:421654 CAPLUS
 DOCUMENT NUMBER: 131:58754
 TITLE: Preparation of substituted pyridine and pyridazine compounds as TNF- α and IL-1 inhibitors
 INVENTOR(S): Mantlo, Nathan B.; Hwang, Chan Kou; Spohr, Ulrike D.
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 188 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932448	A1	19990701	WO 1998-US27298	19981221
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, BR, BU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6174901	B1	20010116	US 1998-215426	19981218
CA 2315827	AA	19990701	CA 1998-2315827	19981221
AU 9920911	A1	19990712	AU 1999-20911	19981221
AU 755421	B2	20021212		
EP 1042293	A1	20001011	EP 1998-965447	19981221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526263	T2	20011218	JP 2000-525385	19981221
PRIORITY APPLN. INFO.:			US 1997-68199P	P 19971219
			US 1998-215426	A 19981218
			WO 1998-US27298	W 19981221

OTHER SOURCE(S): MARPAT 131:58754
 GI



AB Title compds. [e.g., I; R = (S)-NHCH₂CH(NH₂)CH₂Ph; R1 = 4-pyridyl] (II; R2 = substituted Ph) were prepared for use in lowering TNF- α and IL-1


L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 blood levels. Thus, cyclopentenone oxime III, prepd. in 6 steps from 4-pyridinemethanol and 3-MeC₆H₄CHO, underwent Beckmann rearrangement and the dehydrated and chlorinated product acinated by (S)-H₂NCH₂CH(NH₂)CH₂Ph to give II (R2 = C₆H₄Me-3). Data for biol. activity of I were given.
 IT 228392-74-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted pyridine and pyridazine compds. as TNF- α and IL-1 inhibitors)
 RN 228392-74-3 CAPLUS
 CN 1,2-Propanediamine, N1-[6-(4-fluorophenyl)-5-(4-pyridinyl)-3-pyridazinyl]-3-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 228392-98-1P 228392-99-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted pyridine and pyridazine compds. as TNF- α and IL-1 inhibitors)
 RN 228392-98-1 CAPLUS
 CN 3(2R)-Pyridazinone, 6-(4-fluorophenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 228392-99-2 CAPLUS
 CN Pyridazine, 6-chloro-3-(4-fluorophenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1999:350658 CAPLUS
 DOCUMENT NUMBER: 131:5263
 TITLE: Preparation of pyridazine derivatives as interleukin-1 β production inhibitors
 INVENTOR(S): Ohkuchi, Masao; Kyotani, Yoshinori; Shigyo, Hiromichi; Koshi, Tomoyuki; Kitamura, Takahiro; Ohguya, Tadaaki; Matsuda, Takayuki; Yanazaki, Yukiyo; Kawai, Natsuyo; Kotaki, Kyoko; Yoshitaki, Hideo; Habata, Yuriko
 PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925697	A1	19990527	WO 1998-JP5023	19981109
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 11152274	A2	19990608	JP 1997-318133	19971119
CA 2307111	AA	19990527	CA 1998-2307111	19981109
AU 9897626	A1	19990607	AU 1998-97626	19981109
AU 738595	B2	20010920		
BR 9813998	A	20000926	BR 1998-13998	19981109
EP 1043317	A1	20001011	EP 1998-951732	19981109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 504045	A	20010629	NZ 1998-504045	19981109
RU 2209813	C2	20000810	RU 2000-115577	19981109
JP 2000198776	A2	20000718	JP 1998-319281	19981110
JP 3335132	B2	20021015		
TV 502025	B	20020911	TV 1998-87119032	19981117
NO 2000002169	A	20000518	NO 2000-2169	20000427
NO 316021	B1	20031201		
US 6348468	B1	20020219	US 2000-530949	20000515
HK 1032969	A1	20040820	HK 2001-103597	20010524
US 2002123496	A1	20020905	US 2001-996804	20011130
US 2004147516	A1	20040729	US 2004-757525	20040115
US 2005066155	A1	20050324	US 2004-986350	20041112
US 2005267113	A1	20051201	US 2005-203174	20050815
US 2006160804	A1	20060720	US 2006-385995	20060322
PRIORITY APPLN. INFO.:			JP 1997-318132	A 19971119
			JP 1997-318133	A 19971119
			JP 1998-311880	A 19981102
			WO 1998-JP5023	W 19981109
			US 2000-530949	A3 20000515
			US 2001-996804	B1 20011130
			US 2004-757525	B1 20040115
			US 2004-986350	B1 20041112
			US 2005-203174	B1 20050815

L4 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 131:5263
G1




AB The title compds. I [R1 is (substituted) aryl; R2 is Ph substituted with lower alkoxy, lower alkylthio or the like at the position 4; R3 is H, lower alkoxy, lower haloalkyl, lower cycloalkyl, (substituted) aryl, (substituted) arylonyl, (substituted) nitrogenous heterocyclic residue, (substituted) aminocarbonyl or lower alkylcarbonyl; A is a single bond, lower alkylene or lower alkenylene; X is O or S; and the broken line between the carbon atoms at the positions 4 and 5 represents a single or double bond] are prepared. These compds. exhibit excellent inhibitory activity against the production of interleukin 1 β , thus being useful as preventive and therapeutic drugs for immunol. diseases, inflammatory diseases, ischemic diseases and so on. In an in vitro test for inhibition of interleukin-1 β production, 5,6-bis(4-methoxyphenyl)-2-(4-chlorocinnamyl)-2H-pyridazin-3-one showed IC50 of 0.1 μ M.

IT 225666-37-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridazine derivs. as interleukin-1 β production inhibitors)
RN 225666-37-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220967-36-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 220967-37-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 220967-38-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:51061 CAPLUS
DOCUMENT NUMBER: 130:209659
TITLE: Pyridazines. XV. Synthesis of 6-aryl-5-amino-3(2H)-pyridazinones as potential platelet aggregation inhibitors

AUTHOR(S): Estevez, Isabel; Ravina, Enrique; Sotelo, Eddy
CORPORATE SOURCE: Department of Organic Chemistry, Laboratory of Medicinal Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15706, Spain

SOURCE: Journal of Heterocyclic Chemistry (1998), 35(6), 1421-1428
CODEN: JHCCAD; ISSN: 0022-152X
HeteroCorporation


PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Several 3(2H)-pyridazinones with amino groups at C-5 of the pyridazine nucleus have been prepared. The 6-aryl-5-halo-3(2H)-pyridazinones obtained from mucochloric and mucobromic acid lead to the corresponding 5-alkylamino-3(2H)-pyridazinones, which were tested as platelet aggregation inhibitors.

IT 15904-59-3P 220967-35-1P 220967-36-2P
220967-37-3P 220967-38-4P 220967-39-5P
220967-41-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of aryl(amino)pyridazinones with potential platelet aggregation inhibiting activity from amination of aryl(halo)pyridazinones)

RN 15904-59-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 220967-35-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220967-39-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 220967-41-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-[4-(2-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




IT 132814-16-5P 220967-40-8P 220967-42-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aryl(amino)pyridazinones with potential platelet aggregation inhibiting activity from amination of aryl(halo)pyridazinones)
RN 132814-16-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220967-40-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 220967-42-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-[4-(2-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:805157 CAPLUS
 DOCUMENT NUMBER: 128:136324
 TITLE: Pyridazine derivatives. XIV. Study of the vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta: comparison with hydralazine
 AUTHOR(S): Campos-Toimil, M.; Estevez, I.; Ravina, E.; Orallo, F.
 CORPORATE SOURCE: DEPARTAMENTO DE FARMACOLOGIA, FACULTAD DE FARMACIA, UNIVERSIDAD DE SANTIAGO DE COMPOSTELA, SANTIAGO DE COMPOSTELA, E-15706, Spain
 SOURCE: General Pharmacology (1998), 30(2), 201-207
 CODEN: GEHPD; ISSN: 0306-3623
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB 1. For several years we have been working on the synthesis of modified hydrazinopyridazines which have proved to possess remarkable vasorelaxant and antihypertensive activity. We now report the vasodilator effects of three novel 6-aryl-5-piperidino-3-hydrazinopyridazines, structurally related to the well-known antihypertensive drug hydralazine. 2. Hydralazine and the new hydrazinopyridazines relaxed, in a concentration-dependent and non-specific way, the contractions elicited by noradrenaline or a high K⁺ concentration in rat aortic rings with or without endothelium. According to the IC₅₀ (50% inhibitory concns.) values obtained, the vasorelaxant potency of the new compds. was greater than that of hydralazine. 3. In a Ca²⁺-free medium, the contractions provoked by noradrenaline or caffeine were significantly inhibited by the new hydrazinopyridazines and by hydralazine. 4. Hydralazine and the novel mols. did not significantly modify basal, noradrenaline- or K⁺-induced ⁴⁵Ca²⁺ uptake. 5. These results suggest that these hydrazinopyridazines have an endothelium-independent vasorelaxant activity greater than that of hydralazine in isolated rat aortic rings, which seems not to be mediated by a blockade of transmembrane Ca²⁺ movements through specific channels. This effect could be due, at least in part, to an intracellular mechanism of action.


IT 202325-47-1 202325-48-2 202325-49-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta and comparison with hydralazine)

RN 202325-47-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)-, hydrazones (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 202325-48-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 202325-49-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:294193 CAPLUS
 DOCUMENT NUMBER: 125:58060
 TITLE: Synthesis of functionalized phenolic derivatives via the benzannulation of dienyketenes formed by a thermal Wolff rearrangement of α -diazo- β -keto compounds
 AUTHOR(S): Collomb, Didier; Deshayes, Christian; Doutheau, Alain
 CORPORATE SOURCE: Departement Biochimie, Institut National Sciences Appliquees, Villeurbanne, 69621, Fr.
 SOURCE: Tetrahedron (1996), 52(19), 6665-6684
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Eleven conjugated dienyl α -diazo- β -keto derivs. were prepared from α,β -unsatd. carbonyl compds. Their thermolysis induced a Wolff rearrangement generating an intermediate dienyketene whose isomer having the required configuration of the internal double bond underwent a benzannulation to form the corresponding phenolic derivs. When γ -substituted by a methoxy group, both stereoisomers of the diazo compds. gave rise to the phenolic derivs. due to the reversible formation of an intermediate cyclobutenone which permitted the isomerization of the nonproductive transient dienyketene into the productive one.


IT 177979-65-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (functionalized phenolic derivs. via benzannulation of dienyketenes formed by Wolff rearrangement of α -diazo- β -keto compds.)

RN 177979-65-6 CAPLUS
 CN Phosphonic acid, [4-hydroxy-6-phenyl-5-(1-piperidinyl)-3-pyridazinyl]-, dimethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:59299 CAPLUS
 DOCUMENT NUMBER: 116:59299
 TITLE: Synthesis and reactions of some new pyridazinones
 AUTHOR(S): Ismail, A. A.; Radwan, R.; Abdel Hamid, H. A.; Sayed, G. H.; Mohamed, S. M.
 CORPORATE SOURCE: Fac. Sci., Al-Azhar Univ. Girls, Cairo, Egypt
 SOURCE: Journal of the Chemical Society of Pakistan (1991), 13(2), 111-15
 CODEN: JCSPDF; ISSN: 0253-5106
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB β -(p-chlorobenzyl)acrylic acid $\text{ROOCH:CHCO}_2\text{H}$ ($\text{R}=\text{4-ClC}_6\text{H}_4$) reacts with 3-methyl-1-phenyl-2-pyrazolin-5-one to give the adduct I. Reactions of I with hydrazine hydrate and phenylhydrazine afford the corresponding 4-pyrazolinonylpyridazinones II ($\text{R}_1 = \text{H, Ph}$). Reactions of 4-pyrazolinonylpyridazinone II ($\text{R}_1 = \text{H}$) with dimethylsulfate, diethylsulfate, Et bromoacetate, benzenesulfonyl chloride, anisaldehyde, phenylmagnesium bromide and bromine-acetic acid mixture have been described. Reaction of II ($\text{R}_1 = \text{H}$) with POCl_3 yield the chloro derivative III. The behavior of the III towards sodium methoxide, hydrazine hydrate, anthranilic acid and sodium azide has been investigated.

IT 138560-64-22
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 138560-64-2 CAPLUS
 CN Pyridazine, 6-(4-chlorophenyl)-4-(3-methyl-1,5-diphenyl-1H-pyrazol-4-yl)-3-phenyl- (9CI) (CA INDEX NAME)





L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:143314 CAPLUS
 DOCUMENT NUMBER: 114:143314
 TITLE: Pyridazine derivatives. IX. Synthesis of 2H-pyridazin-3-ones with aroylpiperazinyl groups
 AUTHOR(S): Ravina, Enrique; Teran, Carmen; Santana, Lourdes; Garcia, Neftali; Estevez, Isabel
 CORPORATE SOURCE: Fac. Pharm., Univ. Santiago, Santiago de Compostela, 15706, Spain
 SOURCE: Heterocycles (1990), 31(11), 1967-74
 CODEN: HETCYM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:143314
 GI

L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 132814-12-1 CAPLUS
 CN Piperazine, 1-benzoyl-4-(1,6-dihydro-6-oxo-3-phenyl-4-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 132814-13-2 CAPLUS
 CN Piperazine, 1-(1,6-dihydro-6-oxo-3-phenyl-4-pyridazinyl)-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)



AB 2H-Pyridazin-3-ones I ($\text{R} = \text{Ph, 2-furyl}$) were prepared. 6-Phenyl-5-(N4-aro-yl-N1-piperazinyl)-2H-pyridazin-3-ones were obtained by nucleophilic substitution of the chlorine atom of 6-phenyl-5-chloro-2H-pyridazin-3-one II or alternatively, by arylation of N1-piperazinyl-2H-pyridazin-3-ones. Also, 6-phenyl-5-(N4-aro-yl-N1-piperazinylmethyl)-2H-pyridazin-3-ones (III) were prepared by displacement of the bromine in 6-phenyl-5-bromomethyl-2H-pyridazin-3-one (IV).

IT 132814-16-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acylation of, with benzoyl or furonyl chloride)
 RN 132814-16-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 132814-12-1P 132814-13-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as potential antihypertensive agent)


Habte

09/11/2006

L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1990:179002 CAPLUS
 DOCUMENT NUMBER: 112:179002
 TITLE: 5-(1H-imidazol-1-yl)-3(2H)-pyridazinone derivatives as antithrombotics and medicinal fungicides
 INVENTOR(S): Shimamura, Hiroshi; Kosegi, Koji; Yaginuma, Hideya
 PATENT ASSIGNEE(S): Morishita Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01258671	A2	19891016	JP 1987-304986	19871201
PRIORITY APPLN. INFO.:			JP 1987-304986	19871201
OTHER SOURCE(S):		MARPAT 112:179002		

 GI




AB The title compds. I [R1 = H, Cl-14 alkyl, cinnamyl, naphthylsylethyl, (halo-substituted) benzyl or phenoxyethyl; R2 = H, 1H-imidazol-1-yl; R3 = H, (halo-substituted) phenyl] and their acid salts are prepared. Thus, a solution containing 5-chloro-6-phenyl-3(2H)-pyridazinone and imidazole in DMF was stirred 4 h at 140° to give 63% I (R1 = R2 = H, R3 = Ph) (II). II in vitro exhibited IC50 of 46.8 μM and 125.3 μM for arachidonic acid- and collagen-induced aggregation in rabbit blood, resp., vs. >155 and >448, resp., for aspirin. A tablet was prepared from II 50, lactose 200, crystalline cellulose 40, and Mg stearate 5 mg.
 IT 126428-66-8P, 5-(1H-imidazol-1-yl)-6-phenyl-3(2H)-pyridazinone
 126428-67-9P 126461-33-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antithrombotic and medicinal fungicide)
 RN 126428-66-8 CAPLUS
 CN 3(2H)-Pyridazinone, 5-(1H-imidazol-1-yl)-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 126428-67-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 126461-33-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:213879 CAPLUS
 DOCUMENT NUMBER: 106:213879
 TITLE: Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-7(8H)-one: a new heterocyclic ring system from isoxazolo[4,5-b]pyridazinones
 AUTHOR(S): Dal Piaz, Vittorio; Ciciani, Giovanna; Chimichi, Stefano
 CORPORATE SOURCE: Dip. Sci. Farm., Univ. Firenze, Florence, I-50121, Italy
 SOURCE: Heterocycles (1986), 24(11), 3143-8
 CODEN: HETCYM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 106:213879
 GI




AB Treatment of isoxazolo[4,5-b]pyridazinones I (R = H, Me; R1 = Me, Ph; R2 = Ph, 4-ClC6H4) with N2H4 afforded the pyrazole derivs. II which were converted in high yields into the new pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazinones III by ring-closure with Ac2O.
 IT 108311-75-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclocondensation of, with acetic anhydride)
 RN 108311-75-7 CAPLUS
 CN 3(2H)-Pyridazinone, 4-amino-6-phenyl-5-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1986:626436 CAPLUS
 DOCUMENT NUMBER: 105:226436
 TITLE: Studies on some β -aroyl- α -(1,3-disubstituted 5-oxo-2-pyrazolin-4-yl)propionic acids
 AUTHOR(S): Sayed, G. H.; Ismail, A. A.; Hashem, Z.
 CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SOURCE: Egyptian Journal of Chemistry (1985), Volume Date 1984, 27(6), 757-65
 CODEN: EGJCA3; ISSN: 0367-0422
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:226436
 GI




AB Addition of pyrazolinones I (R = Ph, R1 = Me, Ph) to aroylacrylic acids II (R2 = R3 = Cl; R2 = H, R3 = Br) gave adducts III. Cyclocondensation of III with 84KNEH2 (R4 = H, Ph) gave pyridazinones IV. In vitro antibacterial screening of III (R = R1 = Ph; R2 = R3 = Cl; R2 = H, R3 = Br) showed substantial activity against gram-pos. and gram-neg. bacteria.
 IT 94051-61-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 94051-61-3 CAPLUS
 CN 3H-Pyrazol-3-one, 4-[6-(4-bromophenyl)-3-phenyl-4-pyridazinyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1985:571690 CAPLUS
 DOCUMENT NUMBER: 103:171690
 TITLE: Pyridazine derivatives. III. Synthesis and antihypertensive activity of 6-phenyl-5-amino-3-hydrazinopyridazines
 AUTHOR(S): Garcia, G.; Ravina, E.; Santana, L.; Orallo, F.; Calleja, J. M.
 CORPORATE SOURCE: Dep. Quim. Org. Quim. Farm., Univ. Santiago, Santiago, Spain
 SOURCE: Anales de la Real Academia de Farmacia (1985), 51(1), 23-31
 CODEN: ARAFAY; ISSN: 0034-0618
 DOCUMENT TYPE: Journal
 LANGUAGE: Spanish
 OTHER SOURCE(S): CASREACT 103:171690
 GI




AB The title compds. were prepared by multistep syntheses beginning with mucochloric acid [87-56-9]. Mucorchloric acid was reacted with benzene [71-43-2] and AlCl3 to form γ -phenyl- α,β -dichloro- α,β -crotonolactone [72857-85-3] which, after treatment with N2H4 in boiling EtOH, yielded 6-phenyl-5-chloro-3(2H)-pyridazinone [51660-08-3]. Reacting the latter with 3 different cycloamines yielded three 6-phenyl-5-amino-3(2H)-pyridazinones. These, when reacted with P2S5 plus N2H4 or POCl3 plus N2H4 yielded 3 6-phenyl-5-amino-3-hydrazinopyridazines. Of these 3 compds., the strongest antihypertensive activity (comparable with hydralazine) in rats was displayed by 6-phenyl-5-(N4-phenylpiperazinyl)-3-hydrazinopyridazine (I) [98896-19-6].
 IT 98896-19-6P 98896-21-0P 98896-22-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antihypertensive activity of)
 RN 98896-19-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(4-phenyl-1-piperazinyl)-, hydrazone (9CI) (CA INDEX NAME)




RN 98896-21-0 CAPLUS
 CN 3(2H)-Pyridazinone, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl-, Habte


L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 hydrazone (9CI) (CA INDEX NAME)



RN 98896-22-1 CAPLUS
 CN 3(2H)-Pyridazinone, 5-(4-morpholinyl)-6-phenyl-, hydrazone (9CI) (CA INDEX NAME)




IT 98896-29-8P 98896-30-1P 98896-31-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and hydrazone derivatization of)
 RN 98896-29-8 CAPLUS
 CN 3(2H)-Pyridazinone, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 98896-30-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

09/11/2006


L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 98896-31-2 CAPLUS
CN 3(2H)-Pyridazinone, 5-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)




IT 98896-23-2P 98896-24-3P 98896-25-4P
98896-26-5P 98896-27-6P 98896-28-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, with hydrazine)
RN 98896-23-2 CAPLUS
CN Pyridazine, 6-chloro-4-[4-(2-methoxyphenyl)-1-piperazinyl]-3-phenyl- (9CI)
(CA INDEX NAME)




RN 98896-24-3 CAPLUS
CN Pyridazine, 6-chloro-3-phenyl-4-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 98896-25-4 CAPLUS
CN Morpholine, 4-(6-chloro-3-phenyl-4-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 98896-26-5 CAPLUS
CN 3(2H)-Pyridazinethione, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 98896-27-6 CAPLUS
CN 3(2H)-Pyridazinethione, 6-phenyl-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 98896-28-7 CAPLUS
CN 3(2H)-Pyridazinethione, 5-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1985:24542 CAPLUS
DOCUMENT NUMBER: 102:24542
TITLE: Synthesis of some new β -aroyl- α -(4-(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids and 4-pyrazolinonylpyridazinones and the study of their antibacterial activities
AUTHOR(S): Sayed, G. H.; Ismail, A. A.; Hashem, Z.
CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt
SOURCE: Journal of the Chemical Society of Pakistan (1984), 6(2), 95-101
CODEN: JCSPDF; ISSN: 0253-5106
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB $\text{ROOCH:CHCO}_2\text{H}$ ($\text{R} = 4\text{-BrC}_6\text{H}_4$, $3,4\text{-Cl}_2\text{C}_6\text{H}_3$) react with 1,3-disubstituted-2-pyrazolin-5-ones in dry C_6H_6 to give β -aroyl- α -(4(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids (I, $\text{R}_1 = \text{Me}$, Ph). Esterification of I ($\text{R} = 3,4\text{-Cl}_2\text{C}_6\text{H}_3$, $\text{R}_1 = \text{Ph}$) with CH_2N_2 gives the corresponding Me ester. Reactions of I with N_2H_4 and PhNHNH_2 afford the 4-pyrazolinonylpyridazinones II ($\text{R}_2 = \text{H}$, Ph). Dehydration of I yielded the butenolides, which undergo ring opening reaction with amines to give the N-alkylamides of I. Reactions of II ($\text{R}_2 = \text{H}$) with 4-MeOC₆H₄CHO, BrCH₂CO₂Et, Et₂SO₄, and Grignard reagents have also been described. The in vitro antibacterial screening reveals substantial activities against Gram-pos. and Gram-neg. bacteria for I ($\text{R} = 4\text{-BrC}_6\text{H}_4$, $3,4\text{-Cl}_2\text{C}_6\text{H}_3$, $\text{R}_1 = \text{Ph}$) while I ($\text{R}_1 = \text{Me}$) and II ($\text{R} = 3,4\text{-Cl}_2\text{C}_6\text{H}_3$, $\text{R}_2 = \text{Me}$, $\text{R}_2 = \text{H}$) are inactive.


IT 94051-61-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 94051-61-3 CAPLUS
CN 3H-Pyrazol-3-one, 4-[6-(4-bromophenyl)-3-phenyl-4-pyridazinyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1967:482185 CAPLUS
 DOCUMENT NUMBER: 67:82185
 TITLE: Compounds with antineoplastic action. XVIII. Some 4-substituted 3-(p-methoxyphenyl)-6-pyridazinones
 AUTHOR(S): Zikan, Viktor; Semonsky, Miroslav
 CORPORATE SOURCE: Vyzkumny Ustav Farm. Biochem., Prague, Czech.
 SOURCE: Collection of Czechoslovak Chemical Communications (1967), 32(6), 2374-7
 CODEN: CCCCAK; ISSN: 0010-0765
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 66: 95001a. A mixture of 11.6 g. p-MeOC₆H₄COCBr·CHCO₂Me (I) or its cyclic form (II), 6.2 g. N₂H₄ hydrate, and 50 ml. EtOH was stirred at room temperature 48 hrs. to give 90% III, m. 228-9° (EtOH). A mixture of 2.32 g. II and 3.72 g. N₂H₄ hydrate heated 3 hrs. at 115-20° and 3 hrs. at 130-5° gave 100% IV, m. 230-2° (aqueous EtOH), while with I the yield of IV was only 58%. A mixture of 15.2 g. IV and 34.7 g. BzH heated in a sealed tube 7 hrs. at 140° gave 81% V, m. 260-1° (MeOH). Similarly, IV and p-MeOC₆H₄CHO gave 79% VI, m. 243-4° (MeOH). III (1.4 g.) refluxed with 5 ml. C₅H₁₁ON or morpholine 7 hrs. gave 98% VII, m. 212-14° (EtOH), or 86% VIII, m. 268-9° (aqueous EtOH), resp. None of the above pyridazinones III-VIII was more active than the parent I.
 IT 15904-59-3P 15904-60-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 15904-59-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 15904-60-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(p-methoxyphenyl)-5-morpholino- (8CI) (CA INDEX NAME)

L4 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1966:499389 CAPLUS
 DOCUMENT NUMBER: 65:99389
 ORIGINAL REFERENCE NO.: 65:18599h, 18600a-c
 TITLE: 3-Phenyl-4-piperazinylninolines
 INVENTOR(S): Lowrie, Harman S.
 PATENT ASSIGNEE(S): G.D. Searle and Co.
 SOURCE: 3 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3272818		19660913	US 1964-382341	19640713

GI For diagram(s), see printed CA Issue.
 AB Title compds. (I), where R and R₁ are H, F, Cl, Br, I, and Cl-6 alkyl and alkoxy, and R₂ is H, Cl-6 alkyl, alkanoyl, (lower alkoxy)carbonyl, hydroxyethyl, Ph, and PhCH₂, are prepared by the reaction of a halo-substituted phenylcinnoline with a piperazine or an N-substituted piperazine. E.g., a mixture of 4 parts 4-chloro-3-phenylcinnoline, 1 part Cu powder and 20 parts (volume) 1-methylpiperazine was refluxed 1.5 hrs. cooled, diluted with Et₂O, and filtered. The filtrate was washed with dilute KOH, the ether solution extracted with dilute HCl, and the extract was made alkaline, extracted with Et₂O, and dried with saturated NaCl solution and then with anhydr. K₂CO₃. The solvent was evaporated and the residue crystallized from hexane to give I (R = R₁ H, R₂ = Me), m. 128-29°. Also prepared were the I in the table. R, R₁, R₂, M.p.: 4-Cl, H, Me, 151-3°; 4-Me, H, Me, -; 4-OMe, H, Me, 156-7°; H, H, CH₂CH₂OH, 170-3°; H, H, H, 171-3°; H, H, Ac, 209-10°; H, H, CO₂Et, 128-9°; H, H, Ph, 181-2°; H, H, CH₂Ph, 110-11°. The growth of certain bacteria is inhibited by I.
 IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-6882-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-10001-23-7, 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)-10001-25-9, Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)-10001-26-0, 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester 10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-10001-28-2, Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (preparation of)
 RN 6450-85-7 CAPLUS
 CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 6482-16-2 CAPLUS
CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 10001-21-5 CAPLUS
CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10001-27-1 CAPLUS
CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS
CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-23-7 CAPLUS
CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 10001-25-9 CAPLUS
CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 10001-26-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1966:465520 CAPLUS
DOCUMENT NUMBER: 65:65520
ORIGINAL REFERENCE NO.: 65:12203b-c
TITLE: Synthesis of potential antineoplastic agents. XV. Some 1,4-bisamides of 1,2,3,4-tetrahydroquinoxaline
AUTHOR(S): Schuyler, Peter; Popp, Frank D.; Noble, Adria Catala; Alwani, Dru W.; Masters, Barry R.
CORPORATE SOURCE: Clarkson Coll. of Technol., Potsdam, NY
SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 704-7
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB cf. CA 65, 5459c. A number of Cl-containing and unsatd. 1,4-bisamides have been

prepared from 1,2,3,4-tetrahydroquinoxaline and from substituted 1,2,3,4-tetrahydroquinoxalines. Although many of these amides are active against KB cell culture, they are inactive against animal tumors. A number of related amides were also prepared from 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline.


IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-
6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-
10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-
10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-
10001-23-7, 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)-
10001-25-9, Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)-
10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-
10001-28-2, Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl-
10579-35-8, Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl-
10579-38-1, Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)-
10604-38-3, Cinnoline, 3-phenyl-4-piperidino-
10604-48-5, Cinnoline, 4-[4-(2-(dimethylamino)ethyl)piperidino]-3-phenyl-
(preparation of)

RN 6450-85-7 CAPLUS
CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPLUS
CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-21-5 CAPLUS
CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPLUS
CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)

L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10579-35-8 CAPLUS
CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPLUS
CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-25-9 CAPLUS
CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPLUS
CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS
CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10604-38-3 CAPLUS
CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPLUS
CN Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1966:465519 CAPLUS

DOCUMENT NUMBER: 65:65519

ORIGINAL REFERENCE NO.: 65:12203b

TITLE: 3-Phenylcinnolines. II. Preparation of 4-amino derivatives

AUTHOR(S): Lowrie, Harman S.

CORPORATE SOURCE: Div. of Chem. Res., G. D. Searle & Co., Chicago

SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 670-4

CODEN: JMCMAH; ISSN: 0022-2623

DOCUMENT TYPE: Journal


LANGUAGE: English

AB cf. preceding abstract The development of methods for converting 3-phenylcinnoline-4-carboxylic acids into the 4-hydroxy and 4-chloro analogs led to the preparation of 4-amino compds. which were examined for pharmacol. activity. 27 references.

IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-
6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-
10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-
10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-
10001-23-7, 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)-
10001-25-9, Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)-
10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-
10001-28-2, Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl-
10579-35-8, Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl-
10579-38-1, Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)-
10604-38-3, Cinnoline, 3-phenyl-4-piperidino-
10604-48-5, Cinnoline, 4-(4-[2-(dimethylamino)ethyl]piperidino)-3-phenyl-
(preparation of)

RN 6450-85-7 CAPLUS

CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPLUS

CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 10001-25-9 CAPLUS

CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 10001-27-1 CAPLUS

CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS

CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 10001-21-5 CAPLUS

CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 10001-22-6 CAPLUS

CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPLUS

CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 10579-35-8 CAPLUS

CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPLUS


CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 10604-38-3 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 10604-48-5 CAPLUS
 CN Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl- (7CI, 8CI)
 (CA INDEX NAME)




L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1966:465518 CAPLUS
 DOCUMENT NUMBER: 65:65518
 ORIGINAL REFERENCE NO.: 65:12203a-b
 TITLE: 3-Phenylcinnolines. I. Some reactions and derivatives of 3-phenylcinnoline-4-carboxylic acids
 AUTHOR(S): Lowrie, Harman S.
 CORPORATE SOURCE: Div. of Chem. Res., G. D. Searle & Co., Chicago
 SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 664-9
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 65:65518
 AB A series of amide, hydrazide, and ester derivs. of the title acids and 2 phenylbutazone analogs of 3-phenylcinnoline were prepared. These were examined for pharmacol. activity. 21 references.

IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-
 6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-
 10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-
 10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-
 10001-23-7, 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)-
 10001-25-9, Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)-
 10001-26-0, 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester
 10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-
 10001-28-2, Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl-
 10579-35-8, Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl-
 10579-38-1, Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)-
 10604-38-3, Cinnoline, 3-phenyl-4-piperidino-
 10604-48-5, Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl-
 (preparation of)
 RN 6450-85-7 CAPLUS
 CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-21-5 CAPLUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPLUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-25-9 CAPLUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-26-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPLUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-28-2 CAPLUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 10579-35-8 CAPLUS
 CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPLUS
 CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)

L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)

RN 10604-38-3 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPLUS
 CN Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl- (7CI, 8CI) (CA INDEX NAME)

